NCT07693777: A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
- State
- Not started
- Phase
- Phase 3
- People
- 480 planned
- Started
- 17 Aug 2026
- Primary completion
- 14 Feb 2029
- Arms
- Dose 1 DR10624 Group, Dose 2 DR10624 Group
- Results
- None posted
- 9 Jul 2026: Trial registered